Royalty Pharma is a private equity investor founded in 1996 that specializes in purchasing rights to royalties on future drug sales. See contact routes.
Royalty Pharma is a private equity investor founded in 1996 that specializes in purchasing rights to royalties on future drug sales rather than investing in equity. The firm’s investment thesis focuses exclusively on biopharmaceutical royalties, targeting assets that are either approved or in late-stage development across global geographies. Typical transactions involve large check sizes, such as a $900 million royalty purchase from Servier, and the firm consistently acts as a lead buyer in these dedicated royalty deals. Notable portfolio companies include Vertex Pharmaceuticals, whose drug Trikafta is part of Royalty Pharma’s holdings, alongside partial rights to seven of the top 30 selling drugs in the United States. The firm distinguishes itself by providing non-dilutive capital to innovators, including universities and research hospitals, allowing them to fund R&D without equity dilution. Royalty Pharma positions itself as the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the industry, with a portfolio valued at $26.1 billion as of 2026.
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in New York.
Investors like Royalty Pharma · Full investor directory · Investor access · Company funding database